{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:16:28Z","timestamp":1787062588470,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,18]]},"abstract":"<jats:p>\n                    Vonoprazan (VPZ) has been shown to have superior acid-inhibitory effects compared to proton pump inhibitors (PPIs). However, there is a paucity of research examining the efficacy of vonoprazan-based bismuth quadruple therapy (VBQT) in the eradication of primary\n                    <jats:italic toggle=\"yes\">Helicobacter pylori<\/jats:italic>\n                    infection. This study aimed to evaluate the effectiveness and safety of VBQT as a first-line treatment for\n                    <jats:italic toggle=\"yes\">H pylori<\/jats:italic>\n                    eradication. This retrospective, real-world, single-arm study included consecutive treatment-naive patients who received VBQT (VPZ 20\u2009mg, amoxicillin 1000\u2009mg, clarithromycin 500\u2009mg, bismuth potassium citrate 220\u2009mg, all administered twice daily for 14 days) for\n                    <jats:italic toggle=\"yes\">H pylori<\/jats:italic>\n                    eradication between March 1, 2021, and May 30, 2023. The study included both outpatients and inpatients. Eradication rates were assessed using\n                    <jats:sup>13<\/jats:sup>\n                    C-urea breath tests or\n                    <jats:sup>14<\/jats:sup>\n                    C-urea breath tests performed 4 to 6 weeks after treatment. The primary outcomes included eradication rates, adverse events, and treatment compliance. A total of 612\n                    <jats:italic toggle=\"yes\">H pylori<\/jats:italic>\n                    -infected patients were included in the study. The intention-to-treat (ITT), modified ITT (MITT), and per-protocol analyses showed\n                    <jats:italic toggle=\"yes\">H pylori<\/jats:italic>\n                    eradication rates of 84.3% (95% CI: 812% to 87.1%), 95.9% (95% CI: 93.9% to 97.4%), and 96.4% (95% CI: 94.4% to 97.8%), respectively. In the ITT analysis, the adverse event rate was 12.7%, and the treatment compliance rate was 96.9%. In real-world practice, the VBQT regimen demonstrates excellent efficacy and favorable tolerability as a first-line therapy for\n                    <jats:italic toggle=\"yes\">H pylori<\/jats:italic>\n                    eradication.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000040170","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T14:05:20Z","timestamp":1730124320000},"page":"e40170","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of vonoprazan-based bismuth quadruple therapy for first-line Helicobacter pylori eradication: A large-scale, real-world study"],"prefix":"10.1097","volume":"103","author":[{"given":"Jihai","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenen","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin Institute of Digestive Disease, Tianjin Key Laboratory of Digestive Diseases, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7226-7842","authenticated-orcid":false,"given":"Fengyu","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1053\/j.gastro.2009.01.073","article-title":"Helicobacter pylori in health and disease.","volume":"136","author":"Cover","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"R2-20250503","doi-asserted-by":"crossref","first-page":"e12514","DOI":"10.1111\/hel.12514","article-title":"Epidemiology of Helicobacter pylori infection.","volume":"23","author":"Sjomina","year":"2018","journal-title":"Helicobacter"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/apt.13588","article-title":"Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.","volume":"43","author":"Kagami","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R4-20250503","first-page":"gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report.","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"e12475","DOI":"10.1111\/hel.12475","article-title":"Fifth Chinese national consensus report on the management of Helicobacter pylori infection.","volume":"23","author":"Liu","year":"2018","journal-title":"Helicobacter"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the Maastricht V\/Florence Consensus Report.","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.04.012","article-title":"Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: a network meta-analysis.","volume":"161","author":"Rokkas","year":"2021","journal-title":"Gastroenterology"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"e12768","DOI":"10.1111\/hel.12768","article-title":"The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy.","volume":"26","author":"Ke","year":"2021","journal-title":"Helicobacter"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3390\/jcm9061852","article-title":"The impact of gastric juice pH on the intraluminal therapy for Helicobacter pylori infection.","volume":"9","author":"Wang","year":"2020","journal-title":"J Clin Med"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/jcpt.13637","article-title":"Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials.","volume":"47","author":"Yang","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"965","DOI":"10.12669\/pjms.38.4.5436","article-title":"Comparison of vonoprazan and amoxicillin dual therapy with standard triple therapy with proton pump inhibitor for Helicobacter pylori eradication: a randomized control trial.","volume":"38","author":"Zuberi","year":"2022","journal-title":"Pak J Med Sci"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/jgh.15837","article-title":"Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.","volume":"37","author":"Hou","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1751-2980.13166","article-title":"Vonoprazan is non-inferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a propensity score matching analysis.","volume":"24","author":"Wang","year":"2023","journal-title":"J Dig Dis"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"e37476","DOI":"10.1097\/MD.0000000000037476","article-title":"Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: a propensity score matching analysis.","volume":"103","author":"Liu","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"799","DOI":"10.5009\/gnl20242","article-title":"Is a potassium-competitive acid blocker truly superior to proton pump inhibitors in terms of Helicobacter pylori eradication?","volume":"15","author":"Sue","year":"2021","journal-title":"Gut Liver"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/bcp.14934","article-title":"Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.","volume":"88","author":"Huh","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/39.1.5","article-title":"The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection.","volume":"39","author":"Erah","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1046\/j.1365-2036.2003.01592.x","article-title":"Review article the treatment of refractory Helicobacter pylori infection.","volume":"17","author":"M\u00e9graud","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s11894-011-0226-4","article-title":"Gastric infection by Helicobacter pylori.","volume":"13","author":"Sachs","year":"2011","journal-title":"Curr Gastroenterol Rep"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s11938-018-0206-y","article-title":"Potent acid suppression with PPIs and P-CABs: what\u2019s new?","volume":"16","author":"Hunt","year":"2018","journal-title":"Curr Treat Options Gastroenterol"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/ph13100276","article-title":"The potential benefits of vonoprazan as Helicobacter pylori infection therapy.","volume":"13","author":"Miftahussurur","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"e12495","DOI":"10.1111\/hel.12495","article-title":"Systematic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.","volume":"23","author":"Li","year":"2018","journal-title":"Helicobacter"},{"key":"R23-20250503","first-page":"5027","article-title":"A retrospective study of the antibiotic-resistant phenotypes and genotypes of Helicobacter pylori strains in China.","volume":"11","author":"Zhong","year":"2021","journal-title":"Am J Cancer Res"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/apt.17070","article-title":"Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.","volume":"56","author":"Ang","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1111\/jgh.15700","article-title":"Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori.","volume":"36","author":"Bunchorntavakul","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"e12940","DOI":"10.1111\/hel.12940","article-title":"Quadruple therapy with vonoprazan 20\u2009mg daily as a first-line treatment for Helicobacter pylori infection: a single-center, open-label, noninferiority, randomized controlled trial.","volume":"28","author":"Lu","year":"2023","journal-title":"Helicobacter"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"627","DOI":"10.14309\/ajg.0000000000002086","article-title":"Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy.","volume":"118","author":"Qian","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1007\/s10238-023-01074-5","article-title":"Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study.","volume":"23","author":"Peng","year":"2023","journal-title":"Clin Exp Med"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"e12890","DOI":"10.1111\/hel.12890","article-title":"Does technology-enhanced communication improve Helicobacter pylori eradication outcomes?-a meta-analysis.","volume":"27","author":"Chua","year":"2022","journal-title":"Helicobacter"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:18:33Z","timestamp":1746303513000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":29,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040170","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]}}}